FRSQ-RRCancer - biobanque des tumeurs ovariennes, Canada

Certification Status: Approved

Registration Status: Completed

Objective: This biobank is focused on the collection of ovarian cancer clinical samples (lymphocyte DNA, frozen and fixed tissue samples, primary cultures, ascites), as part of the the FRSQ - RÃ©seau de recherche sur le cancer (RRCancer) research activities. The FRSQ-RRCancer has created an infrastructure that supports the ongoing ovarian cancer research in the province of QuÃ©bec, as well as supporting pilot projects for new and innovative research strategies. The collaborations fostered by the RRCancer have shown synergistic effects on the pace and scope of ovarian cancer research in QuÃ©bec. The ovarian initiative was among the first to be supported by the FRSQ-RRCancer because of the strong research base and collaboration already in place. The key activities are tumour banks and the services that support large scale research in genomics and proteomics.

Registered Biobank Name	FRSQ-RRCancer - biobanque des tumeurs ovariennes
Biobank Leader	Dimcho Bachvarov
Country	Canada
Email for biobank inquiries	dimtcho.batchvarov@crhdq.ulaval.ca
Principal Investigator	Dimcho Bachvarov
Website
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper	Poly - Collection aimed at supporting undetermined, multiple users with ethics approved research projects, through a defined access/application mechanism.

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).